Amgen Will Tap Experience With ODAC’s EPO Review To Tackle Renal Panel
Executive Summary
Amgen will use experience gained during FDA's Oncologic Drugs Advisory Committee review of the safety of erythropoiesis-stimulating agents to inform its strategy for a similar meeting of the Cardiovascular and Renal Drugs Advisory Committee this fall
You may also be interested in...
Medicare’s ESA Proposal Relies Too Much On Off-Label Data, Amgen Says
CMS improperly applies safety data from off-label uses of erythropoiesis-stimulating agents to chemotherapy-induced anemia in its recent proposed national coverage determination on ESAs, Amgen maintains
CMS May Take Studious Approach To Covering ESAs In Cancer Setting
CMS is seeking public input on whether Medicare should respond to safety concerns about the use of erythropoiesis-stimulating agents in cancer patients by paying for ESAs only within the context of clinical studies
EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
Sponsors of erythropoiesis-stimulating agents should conduct additional safety studies to support continued marketing in the oncology setting, FDA's Oncologic Drugs Advisory Committee unanimously recommends